A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the
effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in
patients on stable doses of methotrexate, and to further evaluate the safety of the study
drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and
Romania will be enrolled in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer